Matthew Bryant, PharmD

VP Medical Affairs

Dr. Matthew Bryant is the Vice President and Head of Medical Affairs at Boston Pharmaceuticals. He has 25 years of pharmaceutical, biotechnology, and medical device industry experience developing and commercializing numerous new medicines in hepatology, gastroenterology, oncology, respiratory, infectious, and rare diseases. 

 As part of the executive leadership team, he has plays an instrumental role in the clinical development of BOS-580 in MASH at Boston Pharmaceuticals. Previously, he has served on the executive team as Vice President of Medical Affairs for 9 Meters Biopharma where he developed incretin analogues for rare diseases, and Eiger Biopharmaceuticals where he launched a new drug in ultra-rare disease and developed an antiviral for hepatitis. At Bayer Pharmaceuticals he launched three new medicines and worked directly with US payers and healthcare decision-makers as Deputy Director of Data Generation and Outcomes Research. At Theravance Biopharma, he was appointed as the Medical Affairs Launch Leader where he launched a new respiratory drug as part of a strategic partnership with Mylan (Viatris). Over his tenure at Salix Pharmaceuticals, he developed and launched many new drugs in gastroenterology and managed a team of medical science liaisons until Salix was acquired by Valeant Pharmaceuticals (Bausch Health). He also held roles of increasing responsibility at InterMune which was acquired by Genentech, MicroScan (Part of Beckman Coulter), and LifeScan (a Johnson & Johnson company). 

 Dr. Matthew Bryant is an Assistant Clinical Professor at UCSF and serves on the UCSF alumni Board of Governors. He is a Stanford University SPARK start-up advisor. Dr. Matthew Bryant earned a Bachelor of Science degree from Oregon State University, a Doctor of Pharmacy degree from the University of California, San Francisco, and completed an APhA-AMCP specialty residency in Managed Care Pharmacy at Blue Shield of California.